Scipher Hopes IBD Alliance With Galapagos Is The First Of Many

13 Aug 2020

Focused primarily on developing diagnostic tests to determine whether patients will respond to a drug, Scipher is also using the data from its artificial intelligence process to drive R&D partnerships with drug developers.

Abstract matrix digital numbers artifical intelligence ai theme with human face — Scipher uses AI to sort patient data to predict response or non-response to a drug

Artificial intelligence specialist Scipher Medicine has signed an inflammatory bowel disease collaboration with Galapagos that exemplifies what Scipher is hoping to establish as its business model – repurposing the AI it uses to sift through mountains of clinical-genomic patient data for its diagnostics business to also identify novel targets that may lead to drug therapies for non-responding patients. [Editor's note: This article has been corrected to note that Scipher's patient data are not derived from clinical trials.]

Scipher’s primary business is developing blood tests to enable clinicians to determine which autoimmune disease patients likely will or won’t...